Article Listing - Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows

STOCK MARKET COMMENTARY: NEW YORK

13 April 1992

NEW YORK: stock prices climbed throughout nearly the whole rep-orting week, closing with a 40-point or 1.2% rise, following slow...

US NEW PRESCRIPTI0N DRUG SALES IN 1991

13 April 1992

The leading new prescription pharmaceutical product in the USA last year was Wyeth-Ayerst's non-steroidal anti-inflammatory drug Lodine (etodolac), which received...

ROCHE CONSOLIDATED PROFIT LEAPS 56% IN 1991

13 April 1992

For 1991, Swiss pharmaceutical major Hoffmann-La Roche reported "continued and significant improvement in the group's earning performance," with consolidated group...

ORGANON LAUNCHES PHYSIOGINE IN FRANCE

13 April 1992

Organon has launched Physiogine (estriol), in 0.1% vaginal cream and 0.5mg capsule formulations for the local treatment of post-menopausal symptoms,...

ABBOTT 1st QTR NET EARNINGS LEAP 16%

13 April 1992

For the first quarter of 1992, US-based Abbott Laboratories recorded a 15.8% jump in net earnings to $294 million, on...

HAFSLUND GOES FOR ITALIAN MARKET

13 April 1992

The Norwegian pharmaceutical and diagnostics company Hafslund Nycomed has started operations in Italy through its Milan-based subsidiary, and is about...

GYNEX TO MARKET DELATESTRYL

13 April 1992

Gynex Pharma has acquired US marketing rights to Bristol-Myers Squibb's Delatestryl (testosterone) as a treatment for male hypogonadism and delayed...